Collaborators investigate novel T-cell receptor therapy

T cells attacking cancer

Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer.

Elicera Therapeutics will make parts of its technology iTANK available to a medical oncologist and researcher at the undisclosed US cancer centre, whose investigation focuses on the development of novel immunotherapies.

Within the scope of the agreement, the iTANK-platform will be used to arm a novel CD4-directed T-cell receptor therapy (TCR-T), which will be evaluated in preclinical proof-of-concept studies targeting melanoma and lung cancer.

The studies will evaluate the therapy’s effect on tumour growth and activation of other immune cells in the tumour microenvironment. Elicera Therapeutics has the right to utilise the data in its internal project development as well as commercialisation activities, including licensing agreements.

Enhancing treatment for solid tumours

Jamal El-Mosleh, CEO of Elicera Therapeutics, said: “We are excited to enter this collaboration with this well-established cancer centre, to be named upon publication of the research results. A collaboration with an academic partner of such prominence not only provides an increased scientific understanding but also puts Elicera on the map in an ecosystem that includes thought leaders in clinical cell and gene therapy.

“Importantly, the collaboration will give us key insights into the potential of broader applicability of the iTANK-platform, as it will be investigated for arming a T-cell receptor therapy, an important complement to previous studies performed exclusively in CAR T-cells.”

The iTANK technology platform has been developed for arming and enhancing CAR T-cells for the treatment of solid tumours. The technology incorporates a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP), which enhances the function of CAR T-cells and activates a parallel bystander immune response via CD8+ killer T-cells.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free